BioGeneration Ventures

BioGeneration Ventures

https://www.biogenerationventures.com
Last activity: 25.02.2022
Tags:DevelopmentMedicalPlatformTechnologyProductBioTechResearchDrugDiagnosticsHealth
BioGeneration Ventures (BGV) is a venture capital company, with a focus on early stage European biotech, medtech, and diagnostics companies. BGV has a strong track record of significant financial returns through investing in innovations in healthcare and providing the expertise to build world-class teams. The Company manages over €100 million of funds investing in areas where true scientific innovations, the unmet medical need, and the potential to demonstrate a significant proof of concept all come together. BGV strives to work with founding teams to mature science and build companies. The Company uses its experience to guide progress into clinical trials, ultimately leading to successful drug development and value realisation for its investors. BGV applies its expertise in a rigorous process to select the most compelling opportunities with the best prospects for exit. Historical successful investments include divestment of Dezima Pharma to Amgen for up to USD 1.55 billion in total deal value and in Acerta Pharma for up to USD 7 billion with a guaranteed payment of USD 4 billion. Both companies were co-founded by BGV in 2012 and 2013 respectively. The Acerta Pharma sale was the largest exit ever of a privately held European biotech company. BGV is based in Naarden, The Netherlands, and closely collaborates with Forbion.
Team
21
Portfolio
29
References
13
Location:Netherlands, North Holland, Naarden
Member count:11-50
Founded date: 2006
Investment Type: Venture Capital
Investment Stage: Pre-Seed; Seed; Series A

Team 21

DateNameTitleDescriptionLinkedIn
15.09.2021Wouter Ver...Venture Pa...Wouter is a venture partner at...linkedin.c...
15.09.2021Keno Gutie...PartnerKeno joined as a Partner in 20...linkedin.c...
-Roger Ulri...---
-Arnoud Dij...Venture Pa...Arnoud is a venture partner wi...linkedin.c...
-Diede Brun...Senior Ass...Diede Brunen joined BGV as an ...nl.linkedi...
-Stan van B...Professor ...--
-Joost Holt...Venture Pa...Joost has been involved in BGV...linkedin.c...
-Cyril Less...ControllerPreviously, Cyril was a Senior...-
-John Kaste...---
-Paul da Si...---
Show more

Portfolio 29

DateNameDescriptionCategoryWebsiteStatus
25.02.2022VectorY;VectorY is an integrated gene...CNSvectorytx....Current
25.02.2022Complement...Complement Therapeutics is a s...Complement...complement...Current
25.02.2022Brenig;Brenig develops therapies for...Neurologyprnewswire...Current
25.02.2022DunadDunad is Small molecule target...Oncology/C...dunad.co.u...Current
18.08.2021FibrocorFibrocor is developing therape...Autoimmune...fibrocorth...Current
18.08.2021NewAmsterd...NewAmsterdam Pharma acquired D...cardio-met...newamsterd...Current
18.08.2021MironidMironid develops a therapy for...Nephrologymironid.co...Current
18.08.2021Tiga TXTiga TX develops an IgA therap...Oncology-Current
-SynaffixSynaffix BV develops a next ge...Antibody t...synaffix.c...Current
-Dezima Pha...Dezima Pharma develops a best ...Cardiovasc...investors....Exited
Show more

Mentions in press and media 13

DateTitleDescriptionCategoryAuthorSource
01.10.2021BGV closes...Benhamou Global Ventures has r...--pitchbook....
30.09.2021BGV closes...Silicon Valley-based venture c...Anik Bose,...Christine ...techcrunch...
29.06.2020Tech start...The COVID-19 pandemic prevails...european s...Editorial ...siliconcan...
24.06.2020Dutch VC B...BioGeneration Ventures (BGV), ...-Annie Musg...tech.eu/br...
31.07.2019BGV Closes...BGV — an early-stage VC firm w...--pulse2.com...
25.07.2019BGV Comple...BGV, a Palo Alto, CA-based ear...USA-finsmes.co...
01.11.2017Term Sheet...5 Qs WITH A DEALMAKER You may...--fortune.co...
31.10.2017BioGenerat...BioGeneration Ventures (BGV), ...Netherland...-finsmes.co...
31.10.2017Bristol-My...Bristol-Myers Squibb and Johns...Biotech-fiercebiot...
02.07.2017BioGenerat...BioGeneration Ventures (BGV), ...Netherland...-finsmes.co...
Show more